Drug Database
TA

tamsulosin + tolterodine (Roliflo OD)

✓ Approved

Ranbaxy Laboratories Limited · ADRA1A · 小分子

什么是 tamsulosin + tolterodine?

tamsulosin + tolterodine 是一种小分子,由Ranbaxy Laboratories Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Roliflo OD
公司Ranbaxy Laboratories Limited
药物类别小分子
分子靶点ADRA1A, CHRM1, CHRM2, CHRM3, CHRM4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

tamsulosin + tolterodine 作用于 5 个分子靶点:

ADRA1Aadrenoceptor alpha 1A (ADRA1L1, ADRA1C)
CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (EGBRS, m3AChR)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tamsulosin + tolterodine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Renal and urinary disordersHypertonic bladder✓ Approved

相关研究文献

PubMedPakistan journal of medical sciences2026-11-17

Clinical efficacy of mirabegron in the treatment of female patients with Parkinson's disease and overactive bladder.

Li Lanlan L, Yu Huijun H, Zhang Changguo C

To compare short-term clinical outcomes and adverse events associated with mirabegron and tolterodine treatment in female patients with Parkinson's disease (PD) and overactive bladder (OAB). This retrospective cohort analysis included 90 female patients with PD and OAB treated in Huzhou Third Municipal Hospital from January 2021 to October 2024. The final study cohort comprised 45 patients receiving mirabegron and 45 patients receiving tolterodine, selected in a 1:1 ratio with consideration of available baseline clinical characteristics. The primary efficacy outcome was the change in Overactive Bladder Symptom Score (OABSS) from baseline to 12 weeks. Secondary outcomes included changes in urinary diary variables and the occurrence of adverse events, while changes in the Nonmotor Symptoms Scale (NMSS) and Pittsburgh Sleep Quality Index (PSQI) were considered exploratory outcomes. A significant group × time interaction was observed for urgency episodes/24 hours (IRR=0.684, 95% CI 0.515-0.908, P=0.009), indicating a greater reduction over time in the mirabegron group. No significant interactions were observed for nocturia episodes/night (IRR=0.938, 95% CI 0.794-1.108, P=0.450) or micturitions /24 hours(IRR=0.962, 95% CI 0.906-1.021, P=0.202). Significant group × time interactions were also observed for OABSS (estimate=-0.422, 95% CI -0.813 to -0.031, P=0.034) and PSQI (estimate=-1.956, 95% CI -3.098 to -0.813, P=0.001), whereas the interaction for NMSS was not significant (estimate=0.244, 95% CI -0.754 to 1.243, P=0.631). There was no significant difference in the incidence of individual adverse events between the two groups after treatment (P>0.05). However, the proportion of patients experiencing at least one adverse event was significantly lower in the mirabegron group than in the tolterodine group (20.0% vs. 44.4%, P=0.013). In this retrospective cohort of female patients with PD and OAB, mirabegron treatment was associated with greater short-term improvements in selected OAB-related outcomes and sleep quality, as well as a lower proportion of patients experiencing adverse events, compared with tolterodine over 12 weeks. These findings require confirmation in prospective randomized studies.

PMID 43042222
阅读全文 →
PubMedBMC urology2026-11-16

Comparative efficacy and safety of silodosin (Silorap®) versus tamsulosin (Tamsolin®) for medical expulsive therapy of distal ureteral stones.

Khalid Salman El SE, Mithani Muhammad Hammad Ali MHA, Ashraf Hafiz Shahzad HS, Ali Liaquat L et al.

The study objective was to compare the efficacy and safety of Silodosin (Silorap®) versus Tamsulosin (Tamsolin®) in facilitating the passage of acutely obstructing distal ureteral stones. This multicenter, randomized, comparative study enrolled 336 adult patients with a single distal ureteric calculus (5-10 mm) across sixteen tertiary care centers in Pakistan. Participants were randomized to receive Silodosin (Silorap®) or Tamsulosin (Tamsolin®) and followed for 30 days. Primary outcome was stone expulsion rate at four weeks; secondary outcomes included time to expulsion, analgesic use, emergency visits, and safety outcomes. Baseline characteristics were comparable between groups. The stone expulsion rate was significantly higher with Silodosin (112/166; 67.47%) than with Tamsulosin (92/170; 54.12%; p = 0.012). Mean expulsion time was 13.68 ± 8.97 days for Silodosin and 14.33 ± 9.65 days for Tamsulosin (median 12 days; p = 0.701). Kaplan-Meier analysis showed similar time to passage (log-rank p = 0.728). Pain scores declined significantly in both groups. Both treatments were well tolerated; headache and postural hypotension were the most common adverse events, while retrograde ejaculation occurred more frequently with Silodosin. Serious events such as palpitation and syncope were rare and manageable, with no significant differences in vital signs. Silodosin (Silorap®) and Tamsulosin (Tamsolin®) are effective and well tolerated for medical expulsive therapy in distal ureteral stones. Silodosin achieved a higher stone expulsion rate, though time to expulsion was similar between groups. ClinicalTrials.gov ID NCT05977647; Date of registration: 2023-08-04.

PMID 43035721
阅读全文 →
PubMedUrology case reports2026-11-15

A case of spontaneous lens dislocation after initiation of tamsulosin.

Giri Vinay K VK, Kammer Michel M, Garnick Marc B MB

Tamsulosin is an alpha-1-adrenoreceptor antagonist that is commonly prescribed for lower urinary tract symptoms and for prevention of symptoms during prostate radiotherapy. We report the case of an individual with recurrent localized prostate cancer who received tamsulosin 0.4mg daily for one month before and one month after brachytherapy. He then experienced an atraumatic posterior lens dislocation in a congenitally blind left eye. No other explanatory cause of the dislocation was identified. Given tamsulosin's effects on iris dilator muscle and anterior segment support, we recommend further investigation of a possible relationship between alpha-blocker exposure and spontaneous lens dislocation.

PMID 43032743
阅读全文 →
PubMedHealthcare (Basel, Switzerland)2026-11-14

A Tale of Two Pathways: Tamsulosin MET Versus Historical Analgesic-Only Therapy for Pediatric Distal Ureteral Stones.

Ilic Predrag P, Cvetinovic Sava S, Marjanovic Marko M, Cvetinovic Ana A et al.

Background/Objectives: Distal ureteral stones in children can cause severe colic and may lead to persistent obstruction potentially resulting in renal damage if not treated accordingly. This study assessed whether tamsulosin-based MET is associated with higher spontaneous passage of 4-10 mm distal ureteral stones and a lower need for surgery compared with analgesic therapy alone. Methods: In this single-center prospective observational cohort study with a historical comparator, 270 patients aged 5-18 years presenting with renal/ureteral colic and imaging-confirmed distal ureteral stones (4-10 mm) received tamsulosin-based MET (0.4 mg daily) from 2016 to 2023 and were stratified into three age groups. Follow-up included ultrasonography at days 7, 14, and 21. Outcomes were compared with a historical control cohort (2009-2015), involving 242 patients, treated with analgesics alone under the same criteria, follow-up and indications for surgery. The primary outcome was confirmed spontaneous stone passage during the 21-day conservative pathway, before any decision to operate; secondary outcomes included surgery (decision to proceed to ureteroscopy/laser lithotripsy by day 21) and its timing. Results: Spontaneous passage occurred in 78.5% of patients on MET versus 49.6% on analgesics alone (risk difference 28.9 percentage points, 95% confidence interval [CI] 20.7-36.6; p < 0.001), also after adjustment for stone size and hydronephrosis (adjusted odds ratio 4.52, 95% CI 2.95-6.91). Passage was higher with MET in all age groups (exploratory; treatment-by-age interaction p = 0.390), and surgery was decided in 21.5% versus 50.4%. No adverse effects were reported by parents, but they were not systematically recorded. Conclusions: Tamsulosin-based management was associated with a higher observed rate of spontaneous passage and a lower proportion undergoing ureteroscopy than historical analgesic-only care. These findings require cautious interpretation because of the non-contemporaneous comparison and potential confounding by calendar period, stone characteristics and intervention practices.

PMID 43028653
阅读全文 →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-12

[Clinical observation of Sanju Lihe decoction combined with low-intensity pulsed ultrasound in the treatment of type ⅢA prostatitis with qi stagnation and blood stasis].

Long Liuya L, Zhu Wenxiong W, Yuan Yifeng Y, Liu Tao T et al.

Objective To observe the clinical efficacy and safety of Sanju Lihe decoction combined with low-intensity pulsed ultrasound (LIPUS) in the treatment of type ⅢA prostatitis of qi stagnation and blood stasis pattern. Methods From September 2024 to December 2025, a total of 204 patients with type ⅢA prostatitis of qi stagnation and blood stasis pattern treated at the First Hospital of Hunan University of Chinese Medicine were enrolled and randomly divided equally into a control group and a treatment group. The control group received tamsulosin hydrochloride sustained-release capsules, moxifloxacin hydrochloride tablets, Sanju Lihe decoction, and health education. The treatment group was additionally treated with LIPUS on the basis of the control regimen. The treatment course lasted 4 weeks. During the treatment period, the dropped and excluded cases were recorded. Eventually, 195 cases were completed in the study, including 98 cases in the control group and 97 cases in the treatment group. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), 5-item International Index of Erectile Function (IIEF-5), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), traditional Chinese medicine (TCM) syndrome scores, uroflowmetry parameters (Qmax, Qave), grading of leukocytes and lecithin bodies in expressed prostatic secretions, clinical efficacy, and follow-up outcomes were compared between the two groups before and after treatment. Results After treatment, NIH-CPSI scores, TCM syndrome scores, and SAS/SDS scores were improved in both groups compared with baseline (P<0.05). The improvements in NIH-CPSI, IIEF-5, SAS, Qmax, Qave, and leukocyte grading in prostatic secretions were significantly better in the treatment group than those in the control group (P<0.05). No significant differences were observed between the two groups in SDS scores, TCM syndrome scores, or lecithin body grading in prostatic secretions after treatment (P>0.05). The total effective rate was 77.55% in the control group and 92.78% in the treatment group, with a significantly higher rate in the treatment group (P<0.05). At the 4-week follow-up after treatment, NIH-CPSI scores remained lower in the treatment group than in the control group (P<0.05). No serious adverse events occurred in either group during treatment. Conclusion On the basis of conventional medication and health education, Sanju Lihe decoction combined with LIPUS further relieves pain and voiding symptoms, improves sexual function, anxiety status, and uroflowmetry, and alleviates local prostatic inflammation in patients with type ⅢA prostatitis of qi stagnation and blood stasis pattern. The regimen is safe and worthy of clinical application.

PMID 43017717
阅读全文 →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Efficacy of human umbilical cord mesenchymal stem cells in the treatment of chronic nonbacterial prostatitis in rats].

DU Haiyan H, Zhang Kun K, Zhang Qin Q, Li Linghui L et al.

Objective To investigate the efficacy of human umbilical cord mesenchymal stem cell (hUCMSC) for the treatment of chronic nonbacterial prostatitis (CNP) model rats. Methods Thirty-two male Sprague-Dawley rats were randomized into four experimental subgroups: control, model, tamsulosin, and hUCMSC, with eight animals allocated to each group. CNP models were induced in all subgroups, except the control. After 28 days of modeling, the hUCMSC group was injected weekly with 1×106 cells/kg P5 hUCMSC cell suspension by tail vein for 4 weeks. In the control and model groups, equivalent volumes of normal saline were administered via injection. And the tamsulosin group was given daily gavage of 0.022 mg/kg tamsulosin solution for 28 days. After 4 weeks of treatment, the basic indexes including body weight, intake and water intake, and prostate index were analyzed in each group, HE staining was performed to characterize the histopathological features of the prostate. The levels of serum TNF-α, IL-1β, and IL-10 in rats were detected by ELISA. qRT-PCR was used to detect the mRNA expression of TNF-α and IL-1β in prostate tissues. And Western blot was performed to detect the protein expression of the NF-κB inflammatory pathway. Results At the end of treatment, compared with the model group, the body weight and water intake of the rats in the tamsulosin group and hUCMSC group increased significantly (P<0.05). There was a significant decline in prostate indexes and prostate wet weight (P<0.01). And interstitial inflammatory cells in prostate tissues were reduced. The levels of serum TNF-α and IL-1β and the expression of TNF-α and IL-1β mRNA in prostate tissues were significantly reduced (P<0.01). An opposite tendency was observed in IL-10 levels (P<0.01). p-IκBα/IκBα and p-NF-κB p65/NF-κB p65 ratios were significantly reduced (P<0.01). Conclusion hUCMSC improve the pathological state of rat prostate, inhibit the overexpression of pro-inflammatory factors, down-regulate the phosphorylation level of NF-κB signaling pathway, and alleviate the inflammatory response in CNP rats.

PMID 43012244
阅读全文 →

注册免费账户还可查看另外 3371 篇文献

免费注册查看全部文献 →

了解更多tamsulosin + tolterodine